CN101910141B - 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物 - Google Patents

作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物 Download PDF

Info

Publication number
CN101910141B
CN101910141B CN2008801240109A CN200880124010A CN101910141B CN 101910141 B CN101910141 B CN 101910141B CN 2008801240109 A CN2008801240109 A CN 2008801240109A CN 200880124010 A CN200880124010 A CN 200880124010A CN 101910141 B CN101910141 B CN 101910141B
Authority
CN
China
Prior art keywords
amino
added
trifluoropentanamide
methyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801240109A
Other languages
English (en)
Chinese (zh)
Other versions
CN101910141A (zh
Inventor
J·E·小斯塔雷特
K·W·吉尔曼
R·E·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101910141(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101910141A publication Critical patent/CN101910141A/zh
Application granted granted Critical
Publication of CN101910141B publication Critical patent/CN101910141B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2008801240109A 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物 Expired - Fee Related CN101910141B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
US60/984118 2007-10-31
PCT/US2008/079798 WO2009058552A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210178082XA Division CN102718689A (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物

Publications (2)

Publication Number Publication Date
CN101910141A CN101910141A (zh) 2010-12-08
CN101910141B true CN101910141B (zh) 2012-12-19

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008801240109A Expired - Fee Related CN101910141B (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物
CN201210178082XA Pending CN102718689A (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210178082XA Pending CN102718689A (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物

Country Status (28)

Country Link
US (2) US8084477B2 (enExample)
EP (3) EP2205575B1 (enExample)
JP (1) JP5460605B2 (enExample)
KR (1) KR20100075575A (enExample)
CN (2) CN101910141B (enExample)
AR (1) AR069135A1 (enExample)
AT (1) ATE502022T1 (enExample)
AU (1) AU2008319122A1 (enExample)
BR (1) BRPI0818837A2 (enExample)
CA (1) CA2704360A1 (enExample)
CL (1) CL2008003271A1 (enExample)
CO (1) CO6270332A2 (enExample)
CY (2) CY1112337T1 (enExample)
DE (1) DE602008005636D1 (enExample)
DK (2) DK2205575T3 (enExample)
EA (2) EA016447B1 (enExample)
ES (2) ES2390042T3 (enExample)
HR (2) HRP20110219T1 (enExample)
IL (1) IL205406A0 (enExample)
MX (1) MX2010004319A (enExample)
NZ (1) NZ584545A (enExample)
PE (1) PE20091394A1 (enExample)
PL (2) PL2295417T3 (enExample)
PT (2) PT2205575E (enExample)
SG (2) SG174044A1 (enExample)
SI (2) SI2205575T1 (enExample)
TW (1) TW200927099A (enExample)
WO (1) WO2009058552A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935957A (zh) * 2017-12-02 2018-04-20 河南龙湖生物技术有限公司 一种合成高纯度沙坦侧链ttbb的方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325205T3 (es) 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
SG173797A1 (en) * 2009-03-19 2011-09-29 Bristol Myers Squibb Co A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8841458B2 (en) * 2010-03-12 2014-09-23 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
JP2013542973A (ja) * 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキルジベンゾジアゼピノン化合物
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
WO2014047390A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
CN114286828A (zh) 2019-06-24 2022-04-05 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ATE225779T1 (de) 1995-11-17 2002-10-15 Warner Lambert Co Sulfonamidinhibitoren von matrix metalloproteinasen
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CN1224612C (zh) 1999-01-27 2005-10-26 惠氏控股有限公司 炔基磺酰胺硫醇tace抑制剂
MXPA01008606A (es) * 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
EP1454175B1 (en) * 2001-12-14 2011-01-26 Raytheon Company Precisely aligned lens structure and a method for its fabrication
ES2325205T3 (es) 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
NZ535591A (en) * 2002-02-28 2006-07-28 Astrazeneca Ab Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
EP1460070B1 (en) * 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
UA82093C2 (uk) 2003-03-31 2008-03-11 Уайт Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
AR059518A1 (es) 2006-02-17 2008-04-09 Wyeth Corp Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
EP1984347A1 (en) 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935957A (zh) * 2017-12-02 2018-04-20 河南龙湖生物技术有限公司 一种合成高纯度沙坦侧链ttbb的方法
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法

Also Published As

Publication number Publication date
BRPI0818837A2 (pt) 2015-04-22
JP2011502153A (ja) 2011-01-20
JP5460605B2 (ja) 2014-04-02
HRP20110219T1 (hr) 2011-04-30
ATE502022T1 (de) 2011-04-15
PL2295417T3 (pl) 2012-11-30
DK2295417T3 (da) 2012-10-15
CY1112337T1 (el) 2015-12-09
EP2295417A1 (en) 2011-03-16
CN101910141A (zh) 2010-12-08
PT2205575E (pt) 2011-05-23
CL2008003271A1 (es) 2009-07-10
EP2205575A1 (en) 2010-07-14
CY1113346T1 (el) 2016-06-22
EA201171439A1 (ru) 2012-05-30
AU2008319122A1 (en) 2009-05-07
WO2009058552A1 (en) 2009-05-07
MX2010004319A (es) 2010-04-30
PT2295417E (pt) 2012-09-26
US20120088925A1 (en) 2012-04-12
KR20100075575A (ko) 2010-07-02
CO6270332A2 (es) 2011-04-20
NZ584545A (en) 2011-04-29
SI2295417T1 (sl) 2012-11-30
CA2704360A1 (en) 2009-05-07
DE602008005636D1 (de) 2011-04-28
TW200927099A (en) 2009-07-01
ES2361283T3 (es) 2011-06-15
SG174043A1 (en) 2011-09-29
EP2295417B1 (en) 2012-07-04
DK2205575T3 (da) 2011-07-11
HRP20120703T1 (hr) 2012-09-30
CN102718689A (zh) 2012-10-10
SI2205575T1 (sl) 2011-07-29
EP2471769A1 (en) 2012-07-04
PE20091394A1 (es) 2009-09-25
EA201000714A1 (ru) 2010-10-29
US8084477B2 (en) 2011-12-27
AR069135A1 (es) 2009-12-30
US8350084B2 (en) 2013-01-08
SG174044A1 (en) 2011-09-29
US20090111858A1 (en) 2009-04-30
HK1155161A1 (en) 2012-05-11
EA016447B1 (ru) 2012-05-30
ES2390042T3 (es) 2012-11-06
IL205406A0 (en) 2010-12-30
HK1141801A1 (en) 2010-11-19
EP2205575B1 (en) 2011-03-16
PL2205575T3 (pl) 2011-09-30

Similar Documents

Publication Publication Date Title
CN101910141A (zh) 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物
JP2011523412A (ja) スフィンゴシンリン酸受容体の新規なモジュレーター
CN102118972A (zh) 鞘氨醇磷酸酯受体的新调节剂
EP2408450B1 (en) Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN103492361A (zh) 取代的1-苄基环烷基羧酸及其用途
CN102361862A (zh) 用于治疗阿尔茨海默病的噻吩基磺酰胺
EP2408757B1 (en) A novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production
US8093276B2 (en) Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
HK1141801B (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121219

Termination date: 20161014